Rubitection
Low-cost handheld optical device and software for early detection and monitoring of skin breakdown and chronic skin conditions.
Website: https://rubitection.com
Cover Block
PUBLIC
| Name | Rubitection |
| Tagline | Low-cost handheld optical device and software for early detection and monitoring of skin breakdown and chronic skin conditions. |
| Headquarters | Pittsburgh, United States |
| Founded | 2011 |
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed (total disclosed ~$1,300,000) |
Links
PUBLIC
- Website: https://rubitection.com/
- LinkedIn: https://www.linkedin.com/company/rubitection-inc
Executive Summary
PUBLIC
Rubitection is a medical device startup that has developed a low-cost, FDA-cleared handheld scanner to detect early-stage pressure injuries, a persistent and costly problem in healthcare that creates a clear wedge into a larger chronic wound management market [PitchBook, retrieved 2025]. Founded in 2011 by Dr. Sanna Gaspard, a Carnegie Mellon-trained biomedical engineer, the company has progressed from academic research to a 510(k)-cleared product, the Rubitect Assessment System, which combines a proprietary optical probe with care management software [Rubitection website, retrieved 2025][Carnegie Mellon University, August 2013]. The technology's primary differentiator is its focus on early, subclinical detection, aiming to shift care from reactive treatment to proactive prevention, a value proposition underscored by the company's backing from accelerators like Techstars and Luminate and its inclusion in the AgeTech Collaborative from AARP [Techstars, retrieved 2025][Luminate, retrieved 2025].
To date, Rubitection has raised a total of $1.3 million through a mix of traditional seed rounds, government grants, and a recent $409,000 equity crowdfunding round completed in May 2025 [PitchBook, retrieved 2025]. The business model is built on hardware sales paired with software-enabled services, targeting settings from hospitals to home care. The next 12 to 18 months will be critical for validating the company's ambitious revenue projections and scaling commercial deployment, with the ongoing effort to raise an additional $2.0 million in seed capital serving as a near-term milestone for investors to monitor [Tracxn, retrieved 2025].
Data Accuracy: GREEN -- Core company facts, funding totals, and product status are confirmed by multiple independent sources including PitchBook, Crunchbase, and the company's own website.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Seed (total disclosed ~$1,300,000) |
Company Overview
PUBLIC
Rubitection Inc. was founded in Pittsburgh, Pennsylvania in August 2011 by Dr. Sanna Gaspard, a biomedical engineer who developed the core technology during her doctoral research at Carnegie Mellon University [Crunchbase, retrieved 2025]. The company's formation was a direct effort to commercialize a handheld optical device for detecting pressure injuries, an invention stemming from Gaspard's PhD work [Carnegie Mellon University, August 2013].
Key corporate milestones have centered on regulatory progress and non-dilutive funding. The Rubitect Assessment System received 510(k) Premarket Notification from the U.S. Food and Drug Administration, a critical de-risking step for a medical device [Tracxn, retrieved 2025]. The company's funding history reflects a reliance on grant programs and accelerator support prior to its recent equity crowdfunding effort, with early capital from NIH SBIR/STTR awards and placements in accelerators including Techstars, MassChallenge, and the Luminate Accelerator [PitchBook, retrieved 2025].
Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, and primary source material from Carnegie Mellon University.
Product and Technology
MIXED The Rubitect Assessment System is a medical device platform designed to shift wound care from reactive treatment to proactive monitoring. Its core is a handheld optical probe that measures skin properties to detect inflammation and perfusion changes indicative of early-stage pressure injuries, known as bedsores [Rubitection website, retrieved 2025]. The system pairs this hardware with a mobile software application for care management, offering features like risk analytics, severity progression monitoring, and care plan support [Tracxn, retrieved 2025]. The company positions the combined system as a tool for use across home care, nursing homes, and hospitals [Tracxn, retrieved 2025].
A key de-risking milestone for the technology is its 510(k) Premarket Notification clearance from the U.S. Food and Drug Administration [Luminate, retrieved 2025]. This regulatory status allows the device to be marketed for its intended use. The company describes the platform as AI-enabled, which is inferred to apply to the software's analytics for interpreting the optical data and predicting risk [Tracxn, retrieved 2025]. Rubitection is currently running a beta testing and demo program, allowing prospective users to trial the system ahead of a full commercial launch [MTEC, retrieved 2025].
Data Accuracy: GREEN -- Product claims and FDA status are confirmed by the company website and accelerator profiles.
Market Research
PUBLIC The economic and human cost of chronic wounds, particularly pressure injuries, creates a persistent and costly problem for healthcare systems, driving demand for technologies that can reduce incidence and improve care management.
Rubitection's primary target is the market for pressure injury prevention and monitoring. The company cites a total addressable market (TAM) of $4.2 billion for low-risk FDA-cleared technology in this space [Tracxn, retrieved 2025]. This figure appears to be a subset of the broader $11 billion annual cost burden that pressure injuries (bedsores) impose on the U.S. healthcare system, a figure also cited by the company [Tracxn, retrieved 2025]. The broader chronic wound care market, which includes diabetic foot ulcers and vascular leg ulcers, is significantly larger, though specific public sizing for these adjacent segments is not provided in the cited materials.
Demand is anchored in clinical and financial imperatives. Pressure injuries are considered a largely preventable hospital-acquired condition, and since 2008, the Centers for Medicare & Medicaid Services (CMS) has not reimbursed for additional costs associated with treating hospital-acquired stage 3 and 4 pressure ulcers. This policy creates a powerful financial incentive for healthcare providers to invest in early detection and prevention tools. An aging population and rising rates of diabetes and obesity, which are key risk factors for chronic wounds, serve as long-term demographic tailwinds. The shift towards value-based care and home-based care models further incentivizes the adoption of monitoring technologies that can prevent costly complications and readmissions.
Adjacent and substitute markets include the broader digital wound care management segment, which encompasses electronic health record integrations, telehealth platforms for wound consults, and advanced imaging systems. The primary substitute remains the manual, visual skin assessment conducted by nurses and caregivers, a method prone to subjectivity and late detection. The market for point-of-care diagnostic devices in dermatology and podiatry represents another adjacent opportunity for technology that can assess skin perfusion and inflammation.
Regulatory approval is a critical gating factor. Rubitection's device has received 510(k) clearance from the U.S. Food and Drug Administration, a de-risking milestone that allows for commercial sale [Rubitection website, retrieved 2025]. Macro forces include ongoing nursing shortages, which increase the burden on individual caregivers and amplify the need for assistive diagnostic tools, and continued pressure on hospital operating margins, which may accelerate the adoption of cost-saving technologies.
Pressure Injury Cost Burden | 11 | $B
Target Market (Low-risk FDA Tech) | 4.2 | $B
The cited market figures, while not from independent analyst reports, frame the commercial opportunity. The $11 billion cost burden establishes the problem's scale, while the $4.2 billion target suggests the portion of that spend addressable by a device like Rubitection's. The gap between the two figures likely represents costs associated with advanced wound treatment, litigation, and nursing labor that a prevention tool cannot directly capture.
Data Accuracy: YELLOW -- Market sizing figures are company-cited; the $11B pressure injury cost is a widely cited industry statistic.
Competitive Landscape
MIXED Rubitection enters a wound care market where the primary competition is not other startups, but entrenched clinical practice and a single, more expensive, FDA-cleared device. The company’s positioning hinges on offering a lower-cost, more accessible hardware-software alternative to the current standard of care.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Rubitection | Low-cost handheld optical device & software for early detection of skin breakdown (e.g., bedsores). | Seed; ~$1.3M total raised. | Focus on cost and accessibility; AI-enabled software for monitoring and care management. | [PitchBook, retrieved 2025], [Rubitection website, retrieved 2025] |
| Bruin Biometrics (Provizio SEM Scanner) | Handheld scanner using sub-epidermal moisture technology to detect pressure injuries. | Later stage; acquired by Molnlycke Health Care in 2021. | Established clinical evidence and adoption in hospital systems; higher price point. | [Competitor data from structured facts] |
| Manual and visual assessment | Standard clinical practice: visual inspection and manual risk assessment (e.g., Braden Scale). | N/A (practice standard). | Zero incremental cost, deeply embedded in clinical workflows, but subjective and late-stage detection. | [Competitor data from structured facts] |
The competitive map segments into three tiers. At the top, large medtech incumbents like Molnlycke (via its Bruin Biometrics acquisition) offer capital-intensive, hospital-grade solutions with robust clinical validation. Rubitection operates in a challenger tier, targeting the same clinical outcome but with a different technological approach and a stated focus on affordability. The vast, bottom tier is the status quo of manual assessment, which represents both the primary substitute and the enormous addressable market for any technological solution.
Rubitection’s defensible edge today appears to be its regulatory and cost positioning. The company’s 510(k) clearance provides a necessary barrier to entry and de-risks the core device for healthcare buyers [Rubitection website, retrieved 2025]. Its emphasis on being a “low-cost” system, combined with care management software, aims to create a wedge into settings like nursing homes, home care, and rehabilitation where budget constraints limit adoption of higher-priced alternatives [Perplexity Sonar Pro Brief, retrieved 2025]. This edge is perishable, however, if larger incumbents decide to launch lower-cost product lines or if other startups achieve clearance with similar price points.
The company’s most significant exposure is to the entrenched clinical evidence and distribution of the incumbent, Bruin Biometrics. Molnlycke’s sales force and existing hospital relationships create a high barrier to entry in acute care settings, which are often the initial beachhead for new medical devices. Furthermore, Rubitection’s reliance on optical technology versus Bruin’s sub-epidermal moisture approach means it must build its own body of peer-reviewed clinical data to convince skeptical clinicians, a process that requires time and capital.
The most plausible 18-month scenario involves market segmentation rather than winner-take-all competition. Bruin Biometrics (Molnlycke) is the likely winner if the competition remains centered on large hospital procurement, where its scale and evidence base dominate. Rubitection could emerge as a leader in the lower-acuity, cost-sensitive segment,including long-term care and home health,if it successfully deploys its beta program, generates real-world validation data, and closes its targeted $2.0 million seed round to fund commercial rollout [PitchBook, retrieved 2025]. The loser in this scenario is the continued reliance on purely manual assessment, as even modest adoption of either technological solution begins to erode that standard.
Opportunity
PUBLIC
If Rubitection can translate its FDA-cleared optical scanner into a new standard of care for chronic wound management, it is targeting a multi-billion-dollar outcome anchored by the $11 billion annual cost of pressure injuries alone [PitchBook, retrieved 2025].
The headline opportunity is to become the definitive, non-invasive diagnostic platform for early-stage skin breakdown, moving wound assessment from subjective visual inspection to objective, data-driven monitoring. The company’s 510(k) clearance for the Rubitect Assessment System provides a critical regulatory foothold [Rubitection website, retrieved 2025], and its focus on low-cost, handheld hardware paired with care management software creates a wedge into high-volume, cost-sensitive settings like nursing homes and home health. The cited evidence suggests this outcome is reachable, not merely aspirational, because the company has already secured backing from entities like the NIH SBIR/STTR program and the AgeTech Collaborative from AARP [PitchBook, retrieved 2025], indicating validation from both scientific and end-market stakeholders focused on aging populations.
Growth could follow several distinct, concrete paths. The following scenarios outline plausible routes to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Become the CMS-reimbursed standard in post-acute care | The device becomes a mandatory part of skin integrity assessments in skilled nursing facilities (SNFs) to meet quality metrics and avoid penalties. | Securing a specific CPT reimbursement code from the Centers for Medicare & Medicaid Services (CMS). | The device is designed for use in nursing homes and home care [Rubitection website, retrieved 2025], and CMS has a history of creating codes for technologies that reduce costly complications like hospital readmissions. |
| Land-and-expand within large health systems | A pilot in one hospital system's wound care clinic leads to enterprise-wide deployment across affiliated SNFs and home health agencies. | A partnership with a major integrated delivery network (IDN) for a clinical validation study. | Rubitection is listed in the Medical Technology Enterprise Consortium (MTEC) directory, a platform for collaboration with the Department of Defense and large health systems [MTEC, retrieved 2025]. |
| Pivot to a remote patient monitoring (RPM) SaaS model | The software platform, fueled by device data, becomes a subscription service for managing chronic wound patients at home, decoupling growth from hardware sales. | Launch of a standalone software subscription tier and integration with a major electronic health record (EHR) vendor. | The system already includes features for remote monitoring and telehealth [Rubitection website, retrieved 2025], and the founder has cited the $4.2 billion market for low-risk FDA technology [PitchBook, retrieved 2025]. |
Compounding success would likely stem from a clinical data flywheel. Each device scan generates structured data on skin perfusion and inflammation. As the deployed base grows, the aggregated dataset could improve the proprietary algorithms for predicting wound progression, creating a performance moat that becomes harder for new entrants to replicate. Early signs of this flywheel are suggested by the system's described AI-enabled analytics for risk and progression monitoring [Rubitection website, retrieved 2025]. Furthermore, adoption in one wing of a facility could drive expansion to others, as standardized data improves care coordination and reduces liability, creating a workflow lock-in effect.
The size of the win can be framed by a credible comparable. Bruin Biometrics, which markets the Provizio SEM Scanner for pressure injury detection, serves as a direct, though higher-priced, competitor. While its valuation is not public, its existence and focus on a similar clinical problem validate the market need and the potential for a dedicated device company. If Rubitection executes on the "CMS-reimbursed standard" scenario and captures even a single-digit percentage of the U.S. post-acute care market for pressure injury prevention,a segment of the broader $11 billion problem,it could support a venture-scale outcome. A conservative scenario, not a forecast, might see the company achieving a valuation comparable to other specialty medical device companies that have established a new standard of care in a niche but high-cost area of medicine.
Data Accuracy: YELLOW -- Growth scenarios are plausible extrapolations based on product features and market positioning; specific catalyst timelines and partnership details are not publicly confirmed.
Sources
PUBLIC
[PitchBook, retrieved 2025] Rubitection 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/107197-84
[Rubitection website, retrieved 2025] Rubitection | https://rubitection.com/
[Carnegie Mellon University, August 2013] Press Release: Carnegie Mellon Alumna Sanna Gaspard ... | https://www.cmu.edu/news/stories/archives/2013/august/aug12_sannagaspard.html
[Techstars, retrieved 2025] Rubitection | Techstars Job Board | https://jobs.techstars.com/companies/rubitection
[Luminate, retrieved 2025] Rubitection - Luminate | https://luminate.org/rubitection/
[Crunchbase, retrieved 2025] Rubitection - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/rubitection-inc
[Tracxn, retrieved 2025] Rubitection - 2025 Company Profile, Team, Funding & Competitors | https://tracxn.com/d/companies/rubitection/__mlkzCktjauZ5krX0E5KDV2It-V_sKn0_rq7ES_0aiTY
[MTEC, retrieved 2025] Rubitection | MTEC | https://mtec-sc.org/life-sciences/rubitection
[Perplexity Sonar Pro Brief, retrieved 2025] Rubitection | https://platform.tracxn.com/a/d/company/53908152e4b016e6ae0e9cbe/rubitection?utm_source=parallel&utm_medium=ai#a:about
Articles about Rubitection
- Rubitection's Handheld Probe Lands a 510(k) for Bedsores — The Pittsburgh startup's optical scanner aims to catch pressure injuries before they're visible, a bet backed by $1.3 million and a long runway of NIH grants.